Kevin brings over two decades of invaluable biotech and pharma experience to Macomics’ team. He has been CEO at Bicycle Therapeutics since 2015, steering the company through the transition to become a NASDAQ-listed company. His prior Pharma experience includes Pfizer and GSK in research and strategic partnerships.
Steve Myatt, CEO said “Kevin’s experience in building Bicycle Therapeutics and previously in his pharma roles will be extremely valuable in helping us to advance our strong program portfolio towards clinical development and bring next generation macrophage targeting therapeutics to patients with macrophage driven disease.”
You can see the full press release here.
